ReviewFrontiers in immunology2019
Can We Improve Vaccine Efficacy by Targeting T and B Cell Repertoire Convergence?
Review in Frontiers in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 41 citations in OpenAlex.
- Computational mining of B cell receptor repertoires reveals antigen-specific and convergent responses to Ebola vaccination.Frontiers in immunology · 2024Trial
- Characterization of the early cellular immune response induced by HPV vaccines.Frontiers in immunology · 2022Trial
- What Antibody Repertoires See: Structural and Immunogenetic Insights Into Influenza A Virus Hemagglutinin Recognition.Immunological reviews · 2026Review
- Immunotherapy of membranous nephropathy: strategic evolution from CD20 monoclonal antibodies to future vaccines.Frontiers in immunology · 2026Review
- CircRNAs: functions and emerging roles in cancer and immunotherapy.BMC medicine · 2025Review
- Learning the language of antibody hypervariability.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Computational detection of antigen-specific B cell receptors following immunization.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Circular RNA vaccine in disease prevention and treatment.Signal transduction and targeted therapy · 2023Review
- On the feasibility of using TCR sequencing to follow a vaccination response - lessons learned.Frontiers in immunology · 2023Article
- Immune repertoire analysis of normal Chinese donors at different ages.Cell proliferation · 2022Article
- Moving beyond Titers.Vaccines · 2022Review
- Analysis of T cell receptor clonotypes in tumor microenvironment identifies shared cancer-type-specific signatures.Cancer immunology, immunotherapy : CII · 2022Article
- AIRR Community Guide to Planning and Performing AIRR-Seq Experiments.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Predicting epitopes for vaccine development using bioinformatics tools.Therapeutic advances in vaccines and immunotherapy · 2022Review
- COVID-19 vaccine platforms: Delivering on a promise?Human vaccines & immunotherapeutics · 2021Review
- Vaccine-Induced Cellular Immunity againstVaccines · 2021Review
- Biological controls for standardization and interpretation of adaptive immune receptor repertoire profiling.eLife · 2021Review
- Dynamics of thymus function and T cell receptor repertoire breadth in health and disease.Seminars in immunopathology · 2021Review
- Expansion of Human Papillomavirus-Specific T Cells in Periphery and Cervix in a Therapeutic Vaccine Recipient Whose Cervical High-Grade Squamous Intraepithelial Lesion Regressed.Frontiers in immunology · 2021Article
- Biomarkers and Immune Repertoire Metrics Identified by Peripheral Blood Transcriptomic Sequencing Reveal the Pathogenesis of COVID-19.Frontiers in immunology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Traditional vaccine development builds on the assumption that healthy individuals have virtually unlimited antigen recognition repertoires of receptors in B cells and T cells [the B cell receptor (BCR) and TCR respectively]. However, there are indications that there are "holes" in the breadth of repertoire diversity, where no or few B or T cell are able to bind to a given antigen. Repertoire diversity may in these cases be a limiting factor for vaccine efficacy. Assuming that it is possible to predict which B and T cell receptors will respond to a given immunogen, vaccine strategies could be optimized and personalized. In addition, vaccine testing could be simplified if we could predict responses through sequencing BCR and TCRs. Bulk sequencing has shown putatively specific converging sequences after infection or vaccination. However, only single cell technologies have made it possible to capture the sequence of both heavy and light chains of a BCR or the alpha and beta chains the TCR. This has enabled the cloning of receptors and the functional validation of a predicted specificity. This review summarizes recent evidence of converging sequences in infectious diseases. Current and potential future applications of single cell technology in immune repertoire analysis are then discussed. Finally, possible short- and long- term implications for vaccine research are highlighted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.